文献速递瓣膜外科

Carpentier-Edwards环上瓣与Medtronic Mosaic主动脉瓣生物瓣随机试验10年结果

Randomized trial of the Carpentier-Edwards supra-annular prosthesis versus the Medtronic Mosaic aortic prosthesis: 10-year results.
PubMed 文献 · Eur J Cardiothorac Surg · 2018-01-01

前瞻性随机研究比较CE-SAV与Mosaic猪主动脉生物瓣的10年临床表现,394例患者随机分组,10年生存率两组无显著差异,但Mosaic组瓣周漏和瓣膜相关再手术率更高。

要点

  • CE-SAV组10年免于再手术率高于Mosaic组,且无瓣周漏发生。
  • 两组10年生存率、结构性瓣膜毁损、心内膜炎、血栓栓塞和大出血无显著差异。
  • Mosaic组瓣周漏5例、再手术6例,CE-SAV组均为0例。

核心结论

  • 植入10年后,CE-SAV组免于再手术率更高且无瓣周漏发生,CE-SAV与Mosaic主动脉瓣其他方面无显著差异。

研究设计与样本

  • 前瞻性随机研究,2001年1月至2005年3月纳入394例接受生物瓣主动脉瓣置换的患者,随机接受CE-SAV(n=191)或Mosaic(n=203),每年随访共10年。

主要发现

  • CE-SAV组死亡77例(40.3%),Mosaic组死亡93例(45.8%),10年生存率分别为59.7%和54.2%(P=0.27)。
  • 两组结构性瓣膜毁损(P=0.08)、心内膜炎(P=0.95)、血栓栓塞(P=0.06)和大出血(P=0.09)无统计学显著差异。
  • Mosaic组瓣周漏5例、瓣膜相关再手术6例,CE-SAV组均为0例,差异有统计学意义(P=0.02和P=0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We performed a prospective randomized study comparing the clinical performance of the Carpentier-Edwards supra-annular valve (CE-SAV) (Edwards Lifesciences, Irvine, CA, USA) and the newer Mosaic (Medtronic Corporation, Minneapolis, MN, USA) porcine bioprostheses in the aortic position over a 10-year period. METHODS: Between January 2001 and March 2005, 394 patients undergoing bioprosthetic aortic valve replacement were randomized to receive either the CE-SAV (n = 191) or the Mosaic (n = 203) prosthesis. The preoperative demographics, EuroSCORE and intraoperative characteristics concerning cardiopulmonary bypass of the 2 groups were comparable. All patients were followed annually for 10 years. RESULTS: There were 77 (40.3%) deaths in the CE-SAV group and 93 (45.8%) deaths in the Mosaic group. The 10-year survival rate in the 2 groups was 59.7% and 54.2%, respectively (P = 0.27). There were no statistically significant differences between the 2 groups in terms of structural valve deterioration (P = 0.08), endocarditis (P = 0.95), thromboembolism (P = 0.06) and major bleeds (P = 0.09). However, the incidence of paravalvular leaks and valve-related reoperations were higher in the Mosaic group, with 5 leaks and 6 reoperations when compared to none in the CE-SAV group, (P = 0.02) and (P = 0.01) respectively. CONCLUSIONS: At 10 years after implantation, freedom from reoperation was greater in the CE-SAV group with no incidences of paravalvular leaks. There were no other statistically significant differences between CE-SAV and Mosaic aortic prostheses. CLINICAL TRIAL REGISTRATION: clinicaltrial.gov ID 1301 (NCT03346044).

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Zibdeh O, Bugg I, Patel S, et al. Randomized trial of the Carpentier-Edwards supra-annular prosthesis versus the Medtronic Mosaic aortic prosthesis: 10-year results. Eur J Cardiothorac Surg. 2018. PMID: 29401266. doi:10.1093/ejcts/ezx512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。